-
公开(公告)号：US08304408B2
公开(公告)日：2012-11-06
申请号：US12600996
申请日：2008-05-15
CPC分类号： C07D487/04
摘要： The invention provides dBHD-based compositions and dBHD analog compositions, and pharmaceutical compositions comprising them, e.g., in the form of liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these dBHD analogs are used to inhibit a dysfunctional stem cell and/or a cancer (tumor) stem cell.
摘要翻译： 本发明提供了基于dBHD的组合物和dBHD类似物组合物，以及包含它们的药物组合物，例如以脂质体和包含它们的纳米颗粒的形式，以及制备和使用它们的方法。 在一个实施方案中，这些dBHD类似物用于抑制功能障碍的干细胞和/或癌（肿瘤）干细胞。
-
公开(公告)号：US20100203113A1
公开(公告)日：2010-08-12
申请号：US12600996
申请日：2008-05-15
IPC分类号： A61K9/127 , C07D487/04 , A61K31/55 , C12N5/071 , A61P35/00
CPC分类号： C07D487/04
摘要： The invention provides dBHD-based compositions and dBHD analog compositions, and pharmaceutical compositions comprising them, e.g., in the form of liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these dBHD analogs are used to inhibit a dysfunctional stem cell and/or a cancer (tumor) stem cell.
摘要翻译： 本发明提供了基于dBHD的组合物和dBHD类似物组合物，以及包含它们的药物组合物，例如以脂质体和包含它们的纳米颗粒的形式，以及制备和使用它们的方法。 在一个实施方案中，这些dBHD类似物用于抑制功能障碍的干细胞和/或癌（肿瘤）干细胞。
-
3.发明授权Compositions and methods for determining cancer stem cell self-renewal potential 有权用于确定癌症干细胞自我更新潜力的组合物和方法公开(公告)号：US09194862B2
公开(公告)日：2015-11-24
申请号：US12821738
申请日：2010-06-23
CPC分类号： G01N33/5011 , C12Q1/6883 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , G01N33/5073 , G01N2800/50
摘要： In alternative embodiments, the invention provides compositions and methods for determining the self-renewal potential of a cancer stem cell (CSC) through analysis of the cross-talk between cell self-renewal pathways leading to deregulation and enhanced self-renewal of the CSC, or for predicting the drugability (susceptibility to a drug) of a CSC, and/or for predicting the progression of a cancer that corresponds to the CSC, the method comprising detecting and quantifying in CSCs one or more B-cell lymphoma-2 (Bcl-2) family protein isoform(s) or transcripts (mRNAs, messages) encoding one or more Bcl-2 family protein(s) or protein isoform(s) thereof. In alternative embodiments, the invention provides compositions and methods to determine and measure the levels of Wnt, glycogen synthase kinase-3 beta (GSK-3 beta), glycogen synthase kinase-3 alpha (GSK-3 alpha), and/or Sonic Hedgehog Homolog (SHH or Shh) family proteins and alternatively spliced transcripts (mRNAs), and Wnt, GSK3beta, GSK3alpha and/or Shh family protein and alternatively spliced transcript ratios in cancer cells, e.g., stem cells, e.g., CSCs, for diagnostic, drug discovery and prognostic purposes.
摘要翻译： 在替代实施方案中，本发明提供了通过分析导致CSC的去调节和增强的自我更新的细胞自我更新途径之间的串扰来确定癌症干细胞（CSC）的自我更新潜力的组合物和方法， 或用于预测CSC的药物性（对药物的易感性）和/或用于预测与CSC相对应的癌症进展，所述方法包括在CSC中检测和定量一个或多个B细胞淋巴瘤-2（Bcl -2）家族蛋白质同种型或编码一种或多种Bcl-2家族蛋白或其蛋白质同种型的转录物（mRNA，消息）。 在替代实施方案中，本发明提供了确定和测量Wnt，糖原合酶激酶-3β（GSK-3β），糖原合酶激酶-3α（GSK-3α）和/或Sonic Hedgehog的水平的组合物和方法 同源物（SHH或Shh）家族蛋白和可变剪接的转录物（mRNA）和Wnt，GSK3beta，GSK3alpha和/或Shh家族蛋白，以及在癌细胞（例如，干细胞例如CSCs）中的剪接转录物比例用于诊断，药物 发现和预后目的。
-
公开(公告)号：US09611330B2
公开(公告)日：2017-04-04
申请号：US14342384
申请日：2012-09-07
申请人： Catriona H. Jamieson , Qingfei Jiang , Kelly A. Frazer , Christian L. Barrett , Anil Sadarangani , Angela Court , Leslie Crews Robertson
发明人： Catriona H. Jamieson , Qingfei Jiang , Kelly A. Frazer , Christian L. Barrett , Anil Sadarangani , Angela Court , Leslie Crews Robertson
IPC分类号： A61K48/00 , C12N15/11 , C07H21/02 , C07H21/04 , C07K16/40 , A61K31/7105 , A61K31/713 , G01N33/574 , C12N9/80 , C07K2/00 , C12N15/113 , A61K38/00
CPC分类号： C07K16/40 , A61K31/7105 , A61K31/713 , A61K38/00 , C07K2/00 , C12N9/80 , C12N15/1137 , C12Y305/04004 , G01N33/57426 , G01N33/57484 , G01N2333/4703 , G01N2800/52
摘要： In alternative embodiments, the invention provides compositions and methods for inhibiting or ablating cancer stem cells. In alternative embodiments, the invention provides compositions and methods for inhibiting the action of double-stranded RNA-specific adenosine deaminases, or ADAR, enzymes. In alternative embodiments, the invention provides compositions and methods for treating, ameliorating or preventing diseases and conditions responsive to the inhibition of cell differentiation and/or self-renewal of dysfunctional cells, cancer cells, leukemia cells, hematopoietic stem cells or cancer stem cells, e.g., leukemia or Chronic Myeloid Leukemia (CML). In alternative embodiments, the invention provides compositions and methods for inhibiting a Sonic Hedgehog (Shh) pathway, e.g., by using a Smoothened (SMO) protein inhibitor. In alternative embodiments, the invention provides compositions and methods for measuring or determining, or predicting, chronic myelogenous leukemia (CML) progression, Leukemic Stem Cell (LSC) generation and/or tyrosine kinase inhibitor resistance. In alternative embodiments, the invention provides compositions and methods for determining or measuring the effectiveness of a treatment, a drug, a therapy or a diet for eliminating, killing or reducing the amounts of a leukemic stem cell (LSC) or cells.
-
-
-
搜索结果
4 条记录 (耗时 0.028 秒)
